Developing the VTX-1 liquid biopsy system: Fast and label-free enrichment of circulating tumor cells

Developing the VTX-1 liquid biopsy system: Fast and label-free enrichment of circulating tumor cells
Diagram of how the Vortex Biosciences technology works. A blood sample flows down the micro-channels in the Vortex chip which is designed to form micro-vortices. These micro-vortices trap and retain the CTCs while the blood cells flow past. Once isolated, the CTCs can be released for downstream analysis. Credit: Marc Lim.

A new article in the February 2018 issue of SLAS Technology describes a new platform that could change the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells (CTCs) directly from cancer patient blood. Entitled Fast and Label-Free Isolation of Circulating Tumor Cells from Blood: From a Research Microfluidic Platform to an Automated Fluidic Instrument, VTX-1 Liquid Biopsy System, this article provides unique insight into the development of a commercial system that has the potential to change the standard of care in cancer diagnosis and treatment.

CTCs can be isolated from a simple draw and may be representative of the diverse patient biology because are circulating in the blood stream from multiple tumor sites. The VTX-1 Liquid Biopsy System was designed to automate the isolation of clinically relevant CTC populations, making the CTCs available for easy analysis by a variety of techniques. In this publication, the transition from a cutting-edge microfluidic innovation in the research setting to a commercial, automated system for isolating CTCs directly from whole blood is outlined.

A number of improvements are reviewed as the technology transitioned into a commercial product. These improvements include better material for the microfluidic fabrication, automating the fluid processing in the chip, and the optimization of protocols. The commercial VTX-1 Liquid Biopsy System is shown to recover spiked breast and lung cancer cell lines at a rate of 69% and 79.5% respectively while achieving a purity as low as <100 white blood cells per mL of blood processed.

To show the utility of the platform for cancer research, several downstream applications are demonstrated on the CTCs isolated by the VTX-1. Clonogenic and cell invasion assays demonstrate that the cells isolated by the VTX-1 are intact and undisturbed by the processing, resulting in direct access to the cell's cancer biology. To demonstrate that the VTX-1 can also process mouse samples, CTCs are isolated from two patient-derived orthotopic xenograft mouse models.

More information: Cristina Zavaleta et al, Theranostic Nanoparticles for Tracking and Monitoring Disease State, SLAS TECHNOLOGY: Translating Life Sciences Innovation (2017). DOI: 10.1177/2472630317738699

Provided by SLAS (Society for Laboratory Automation and Screening)
Citation: Developing the VTX-1 liquid biopsy system: Fast and label-free enrichment of circulating tumor cells (2018, January 22) retrieved 28 February 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Circulating tumor cells associated with relapse in late-stage melanoma patients


Feedback to editors